Camurus AB (publ) is a Swedish science-led biopharmaceutical company founded in 1991 and headquartered in Lund, specializing in the research, development, and commercialization of innovative, long-act... Camurus AB (publ) is a Swedish science-led biopharmaceutical company founded in 1991 and headquartered in Lund, specializing in the research, development, and commercialization of innovative, long-acting medicines for severe and chronic diseases. The company leverages its proprietary FluidCrystal technology, which utilizes lipid lyotropic liquid crystal nanostructures to enable controlled, sustained release of active pharmaceutical ingredients such as peptides, proteins, and small molecules. This platform supports injectable depots for extended therapeutic delivery from a single dose and topical bioadhesive systems for local treatment. Camurus addresses critical unmet needs in areas including opioid dependence with products like Buvidal and Brixadi, acromegaly with Oczyesa, pain management, cancer, endocrine disorders, oncology supportive care, metabolic diseases, and rare conditions. With over 250 employees across offices in Europe, the US, and Australia, Camurus collaborates with global pharmaceutical partners like Novartis and Braeburn to advance its diversified clinical pipeline, enhancing patient outcomes, treatment adherence, and quality of life through best-in-class potential therapies.
We have not yet reviewed Camurus's disclosures for Group Entities data.
If this data is relevant to your work, you can submit a data coverage request and our team
will investigate the company's disclosures and capture the data if available.